Envista Holdings Corp (NVST) is a publicly traded company in the Healthcare — Medical - Instruments & Supplies industry listed on NYSE. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Envista Holdings Corporation is an enterprise dedicated to the development and distribution of a comprehensive range of dental solutions. These offerings are crucial for the identification, therapeutic intervention, and preventative care of diverse oral health issues, specifically addressing the teeth, gingiva (gums), and their supporting bone structures.
Is Envista Holdings Corp stock overvalued or undervalued in 2026?
Envista Holdings Corp (NVST) trades at 41.3× earnings (P/E), above the median of the 246 healthcare companies over $2bn in Kaplio's universe. At its sector median (30.4×) $18 (-26 %).
Kaplio overview: Envista Holdings Corp
Market cap $4B · 52 weeks $19 – $30 (21 % below the high) · P/E 41.3× · 2027 expected P/E 14.4× · Dividend none · Next earnings November 4, 2026 · expected EPS $0.36 · Closing price, Oct 28 · accounts published Aug 5.
- Valuation: P/E 41.3× (expensive).
- Business: ROIC 2 % (weak).
- Balance sheet: Net debt/EBITDA 1.2× (solid).
- Earnings: 8 of 8 (on track).
What would it be worth at its usual multiples?
At its sector median (30.4×) $18 (-26 %). Implied price from applying the reference multiples to today's earnings (or book value, or FFO) per share. Not a fair value: it is where the stock would trade at its usual multiples.
What matters in pharma: 3 of 7 pass
- R&D / Revenue 4.2 %, fails.
- 5y EPS growth 6.0 %, fails.
- Gross margin 55.0 %, fails.
- ROIC 2.4 %, fails.
- FCF / Net Income 490.2 %, passes.
- Net debt / EBITDA 1.2×, passes.
- P/E vs own 10y history 41.3×, passes.
Against its peers (reference peers) — Envista Holdings Corp: P/E 41.3×; EV/EBITDA 10.4×; ROIC 2.4 %; $3.8B. ICU Medical, Inc. (P/E 141×; EV/EBITDA 20.4×; ROIC -21.7 %; $4.2B), Concentra Group Holdings Parent, Inc. (P/E 26.4×; EV/EBITDA 15.4×; ROIC 10.5 %; $5.2B), Privia Health Group, Inc. (P/E 101×; EV/EBITDA —; ROIC 0.0 %; $2.8B).
Profitability
| Return on Equity | 3.08% |
| Return on Invested Capital | 2.38% |
| Return on Assets | 1.70% |
| Gross Margin | 55.50% |
| Operating Margin | 9.92% |
| Net Margin | 3.33% |
Financial Health
| Debt / Equity | 0.52 |
| Current Ratio | 2.43 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 1.60 |
Price Performance
| 1 month | +2.61% |
| 3 months | -12.34% |
| Year-to-date | +10.27% |
| 1 year | +19.82% |
| 3 years | +2.79% |
| 5 years | -38.77% |
Related companies: ICUI · DYN · SUPN · PRVA · GRAL · CON
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of NVST: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks